<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142886">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01850784</url>
  </required_header>
  <id_info>
    <org_study_id>132/2013</org_study_id>
    <nct_id>NCT01850784</nct_id>
  </id_info>
  <brief_title>High Energy Formula Feeding in Infants With Congenital Heart Disease</brief_title>
  <official_title>High Energy Formula Feeding in Infants With Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Sami Ulus Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Sami Ulus Children's Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High energy formula more positively affect growth in infants with congenital heart disease
      compared to standard formula
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants with congenital heart disease (CHD) usually show growth retardation as they can not
      intake enough calorie due to fluid restriction. We hypothesize that high energy formula more
      positively affect growth in infants with congenital heart disease compared to standard
      formula
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Weight gain</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental evaluation</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Neurodevelopmental evaluation will be assessed by Bayley-II Scale at corrected age of 12-18 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Growth Failure</condition>
  <condition>Neurodevelopmental Disorder</condition>
  <arm_group>
    <arm_group_label>High energy formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High energy formula (Similac)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High energy formula</intervention_name>
    <description>The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)</description>
    <arm_group_label>High energy formula</arm_group_label>
    <other_name>High energy formula (Similac)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard formula</intervention_name>
    <description>The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)</description>
    <arm_group_label>Standard formula</arm_group_label>
    <other_name>Standard formula</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infants &gt;35 weeks of gestational age

          -  infants with CHD

          -  İnfants fed with formula feeding

        Exclusion Criteria:

          -  Major congenital abnormalities except CHD

          -  infants could not be fed enterally
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilek Dilli</last_name>
    <role>Study Director</role>
    <affiliation>Sami Ulus CH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dilek Dilli, Assoc Prof</last_name>
    <phone>00903126243</phone>
    <email>dilekdilli2@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sami Ulus CH</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazan N Doğan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nazan N Doğan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 8, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Sami Ulus Children's Hospital</investigator_affiliation>
    <investigator_full_name>Dilek Dilli</investigator_full_name>
    <investigator_title>Assoc Prof</investigator_title>
  </responsible_party>
  <keyword>Congenital heart disease, Growth,Neurodevelopment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Failure to Thrive</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
